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BACKGROUND: Previous studies have reported associations between attention-deﬁcit/hyperactivity disorder
symptoms and DNA methylation in children. We report the ﬁrst epigenome-wide association study meta-analysis
of adult attention-deﬁcit/hyperactivity disorder symptoms, based on peripheral blood DNA methylation (Inﬁnium
HumanMethylation450K array) in three population-based adult cohorts.
METHODS: An epigenome-wide association study was performed in the Netherlands Twin Register (N = 2258, mean
age 37 years), Dunedin Multidisciplinary Health and Development Study (N = 800, age 38 years), and Environmental
Risk Longitudinal Twin Study (N = 1631, age 18 years), and results were combined through meta-analysis (total
sample size N = 4689). Region-based analyses accounting for the correlation between nearby methylation sites
were also performed.
RESULTS: One epigenome-wide signiﬁcant differentially methylated position was detected in the Dunedin study, but
meta-analysis did not detect differentially methylated positions that were robustly associated across cohorts. In
region-based analyses, six signiﬁcant differentially methylation regions (DMRs) were identiﬁed in the Netherlands
Twin Register, 19 in the Dunedin study, and none in the Environmental Risk Longitudinal Twin Study. Of these
DMRs, 92% were associated with methylation quantitative trait loci, and 68% showed moderate to large blood-
brain correlations for DNA methylation levels. DMRs included six nonoverlapping DMRs (three in the Netherlands
Twin Register, three in the Dunedin study) in the major histocompatibility complex, which were associated with
expression of genes in the major histocompatibility complex, including C4A and C4B, previously implicated in
schizophrenia.
CONCLUSIONS: Our ﬁndings point at new candidate loci involved in immune and neuronal functions that await
further replication. Our work also illustrates the need for further research to examine to what extent epigenetic as-
sociations with psychiatric traits depend on characteristics such as age, comorbidities, exposures, and genetic
background.
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https://doi.org/10.1016/j.biopsych.2019.02.016Attention-deﬁcit/hyperactivity disorder (ADHD) is among the
top-ranking psychiatric diagnoses in children and adults (1)
and appears to reﬂect the extreme end of a continuous dis-
tribution of ADHD symptoms in the population (2–4). Genetic
association studies have identiﬁed common and rare variants
associated with ADHD (4–6). Numerous environmental risk
factors have been reported, including prenatal and perinatal
factors (7) [birth weight (8), prenatal exposure to maternal
smoking (9), toxins (7), maternal fever and infections (10)] and
postnatal factors [childhood maltreatment (11), current stress
(11), infections (12)]. Recent studies have investigated if DNA
methylation levels, which regulate gene expression, are asso-
ciated with ADHD (13–25). DNA methylation may represent aSEE COMMENTARY
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N: 0006-3223 Biologmarker that captures the cumulative effects of genetic variants,
stochastic effects, and environmental exposures (26,27)
associated with a trait. Several prenatal exposures, including
maternal famine (28), maternal folate (29), and maternal
smoking (30), and later life exposures, for example, smoking
(31), have been associated with stable long-term changes in
DNA methylation in blood and other peripheral tissues.
Importantly, DNA methylation patterns are largely tissue spe-
ciﬁc. ADHD symptom level–associated DNA methylation dif-
ferences in peripheral tissues such as blood are likely to reveal
epigenetic consequences of differential life conditions that
correlate with ADHD (biomarker of exposures). The extent to
which DNA methylation in peripheral tissues is informativeON PAGE 570
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differences in ADHD symptoms or that correlate with causal
epigenetic mechanisms in other tissues is unknown. It has
been reported that DNA methylation levels in blood correlate to
a limited extent with methylation levels in other tissues,
including the brain (32–35). One explanation for such correla-
tions is that methylation quantitative trait locus (mQTL) effects
correlate to some extent across tissues, as was recently
demonstrated for cis mQTL effects in blood and brain (36).
Several candidate gene studies, most of limited sample size
(mean 192; range, 82–426), have reported associations be-
tween ADHD symptoms in children and DNA methylation in
cord blood (13), peripheral blood (14,18,20), buccal samples
(22), and saliva (19,20). Other candidate approaches in small
samples have reported relationships between DNA methyl-
ation, ADHD symptoms, and environmental risk factors
(15,21,23). To date, three epigenome-wide association studies
(EWASs) of ADHD (symptoms) in children have been published
(16,19,24). The ﬁrst study measured DNA methylation in saliva
in a small group of boys with ADHD and control subjects (age
7–12 years, sample size = 112) and reported genes with sug-
gestive evidence for association (19). The second study
measured DNA methylation in 384 cord blood samples and
found no signiﬁcant differences between children who later
received a diagnosis of ADHD and controls (24). The largest
EWAS (817 children in a population-based study in the United
Kingdom) identiﬁed 13 loci, where DNA methylation level in
cord blood was signiﬁcantly predictive of ADHD symptom
trajectories between age 7 and 15 years (16); among those was
ST3GAL3, one of the signiﬁcant loci from the genome-wide
association study (GWAS) of ADHD (4). As both DNA methyl-
ation and ADHD symptoms change with age, it is unknown if
ﬁndings in children persist in adulthood. Moreover, the
robustness of associations between ADHD symptoms and
DNA methylation remains to be investigated in larger studies of
multiple cohorts.
We report the ﬁrst EWAS meta-analysis of ADHD symptoms
in adults; this is also the largest EWAS of ADHD symptoms to
date. We assessed the association between whole-blood DNA
methylation and ADHD symptoms in three population-based
cohorts: the Netherlands Twin Register (NTR), the Dunedin
Multidisciplinary Health and Development Study from New
Zealand, and the Environmental Risk (E-Risk) Longitudinal
Twin Study from the United Kingdom. In secondary analyses,
we 1) tested if CpGs with a lower, albeit nonsigniﬁcant, p value
showed enrichment for loci previously identiﬁed in GWASs of
psychiatric disease or in EWASs of psychiatric phenotypes or
exposures; 2) analyzed differentially methylated regions
(DMRs) to examine the evidence for small methylation differ-
ences at multiple nearby CpGs; and 3) examined the rela-
tionship between DNA methylation and RNA transcript levels in
blood, the effects of mQTLs, and the correlation between DNA
methylation in blood and brain to facilitate the biological
interpretation of ﬁndings.
METHODS AND MATERIALS
Overview
The EWAS was performed in three cohorts (Figure 1): NTR (37)
(N = 2232 individuals from twin families), Dunedin study (38)600 Biological Psychiatry October 15, 2019; 86:599–607 www.sobp.or(N = 800 unrelated individuals), and E-Risk (39) (N = 1631
twins). Results were combined in a meta-analysis to identify
differentially methylated positions (DMPs) and to examine
heterogeneity of effects across cohorts. Next, we performed
secondary analyses. Genome-wide meta-analysis test statis-
tics were used to test for enrichment of ADHD EWAS signals in
loci detected in previous GWASs and EWASs of relevant traits.
We performed DMR analyses in each cohort, compared results
across cohorts, and performed a meta-analysis–based DMR
analysis. Functional follow-up analyses were performed on top
DMPs from the meta-analysis (nominal p value , 1.0 3 1025)
and on signiﬁcant DMRs. Further details about the analyses
are provided in Supplement 1.
Ethical Permission
The study protocol was approved by the institutional ethical
review boards of the participating universities. Study members
gave informed consent before participating. Written informed
consent was obtained from all participants.
ADHD Symptoms
The EWAS in NTR was performed on the Conners Adult ADHD
Rating Scale (CAARS) index (total ADHD symptoms)
(Figure S1A in Supplement 1) (40). Sensitivity analyses were
performed on DSM-IV–based CAARS inattention and hyper-
activity subscales, available for 1846 samples. In the Dunedin
study, DSM-5 ADHD symptoms (Figure S1B in Supplement 1)
were assessed based on private structured interviews as
described previously (41) at age 38 years. In the E-Risk study,
DSM-5 ADHD symptoms (Figure S1C in Supplement 1) were
assessed based on private structured interviews as described
previously (42) at age 18 years.
Peripheral Blood DNA Methylation
DNA methylation was assessed with the Inﬁnium Human-
Methylation450K BeadChip Kit (Illumina, Inc., San Diego, CA).
Normalization was performed with functional normalization in
NTR (43), with methylumi in the Dunedin Study, and with dasen
in E-Risk (44). The following probes were removed from all
cohorts: sex chromosomes; probes with a single nucleotide
polymorphism (SNP) within the CpG site (at the C or G posi-
tion), regardless of minor allele frequency, based on the
Genome of the Netherlands reference population (45); probes
with common (.5% minor allele frequency) SNPs within 10 bp
of the single base extension site (46); and ambiguous mapping
probes with an overlap of at least 47 bases per probe (47). Only
methylation sites that were present in all cohorts were kept in
the analysis, leaving 394,194 sites.
Statistical Analyses
Epigenome-wide Association Study. The association
between DNA methylation levels and ADHD symptoms was
tested for each site under a linear model (Dunedin) or gener-
alized estimating equation model accounting for relatedness of
twins and other family members (NTR and E-Risk); methylation
b value was assessed as outcome, and the following pre-
dictors were used: ADHD symptoms, sex, smoking status,
white blood cell percentages, age at blood sampling (only in
NTR), cohort-speciﬁc technical covariates (i.e., sample plateg/journal
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Figure 1. Summary of analyses of epigenome-
wide association study (EWAS) in three cohorts:
Netherlands Twin Register (NTR), Dunedin Multi-
disciplinary Health and Development Study from
New Zealand, and Environmental Risk (E-Risk)
Longitudinal Twin Study. DMR, differentially meth-
ylated region; GWAS, genome-wide association
study; mQTLs, methylation quantitative trait loci.
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probes), and principal components based on genome-wide
SNPs. Analyses were performed in R (R Foundation for Sta-
tistical Computing, Vienna, Austria). The R package Bacon was
used to compute the Bayesian inﬂation factor (48).
Meta-analysis. A p value–based ﬁxed-effects sample size–
weighted meta-analysis was performed in METAL (49). The
sample size–weighted method was chosen because of the
differences in measurement scales of ADHD symptoms across
studies. Statistical signiﬁcance was assessed considering
Bonferroni correction for the number of methylation sites
tested (a = .05/394194 = 1.3 3 1027). False discovery rate Q
values are presented in Supplemental Tables S1 through S14
in Supplement 2. The I2 statistic provided by METAL was
evaluated to assess heterogeneity.
Inattention and Hyperactivity. For top DMPs, sensitivity
analyses were performed in which the association of these
DMPs with inattention and hyperactivity/impulsivity subscales
was tested in NTR.
Overlap With EWAS and GWAS Loci. Enrichment anal-
ysis was performed to examine whether CpGs in or near loci
detected by GWASs or top-ranking CpGs from previous
EWASs, on average, showed a stronger association with
ADHD symptoms than other genome-wide Inﬁnium Human-
Methylation450K methylation sites. We considered the most
recent GWASs for ADHD (4), major depressive disorder (50),
schizophrenia (51), and autism spectrum disorder (52) and the
largest available EWASs on ADHD symptoms in children (16),
schizophrenia (53), smoking (31), and maternal smoking (30).
Differentially Methylated Regions. We used the python
module comb-p (54) to identify regions where multiple corre-
lated methylation sites show evidence for association with
ADHD symptoms. We report signiﬁcant regions (Sidák p , .05)
with at least two methylation sites within a 500-bp window.
Comb-p was applied in each of the three cohorts separately
and on the meta-analysis results.
Functional Follow-up Analyses. In follow-up analyses,
previously published datasets were used to test if DNA
methylation level at top DMPs and at CpGs within signiﬁcant
DMRs were associated with whole-blood gene expression
level in cis (55) and with whole-blood mQTLs (55) and toBiological Psyexamine the correlation between DNA methylation in blood
and four brain regions (prefrontal cortex, entorhinal cortex,
superior temporal gyrus, and cerebellum) (34).
Power Analysis. Power analyses are described in
Supplement 1.
RESULTS
Meta-analysis
Demographic information of the cohorts is provided in Table 1.
Genome-wide EWAS test statistics from each cohort showed
no inﬂation (Figure S2 in Supplement 1; Table S1 in
Supplement 2). One signiﬁcant DMP (a = 1.3 3 1027) was
detected in Dunedin (cg26197679, chromosome 8 intergenic)
and none in NTR and E-Risk. Meta-analysis of the three co-
horts (N = 4689) detected no signiﬁcant DMPs, and meta-
analysis test statistics showed no inﬂation (Figure S2 in
Supplement 1; Table S1 in Supplement 2). Summary statistics
for genome-wide methylation sites are provided in Table S2 in
Supplement 2. Top DMPs with a nominal p value (p , 1.0 3
1025) are presented in Table 2. Two top DMPs showed a
negative relationship with ADHD symptoms (cg26197679,
intergenic, and cg23144852, gene body OPA1), and one DMP
showed a positive relationship with ADHD symptoms in all
cohorts (cg10984962, gene body AGAP1). The effect sizes for
these DMPs in the individual cohorts are presented in Table S3
in Supplement 2. In NTR, an increase of 1 SD in CAARS ADHD
symptoms (3.9 points) was associated with a methylation
change of 20.04% (cg26197679), 20.16% (cg23144852), and
0.10% (cg10984962).
Heterogeneity of Top DMPs
One top DMP (cg26197679) displayed large between-study
heterogeneity (I2 = 93.6%, heterogeneity p = 1.6 3 1027). This
DMP showed the strongest association with ADHD symptoms
and was epigenome-wide signiﬁcant in the Dunedin study,
where an increase of 1 SD in DSM-5 ADHD symptoms was
associated with a methylation change of20.62%. Although the
effect size was weaker in the other cohorts, the direction of
association was the same in all cohorts (Table 2). Inspection of
all top-ranking sites from the individual cohorts (p, 1.03 1025:
14 sites) revealed that all sites were characterized by substantial
between-study heterogeneity (mean I2 = 87.2%; range, 71.3%–
93.8%) (Table S4 in Supplement 2). Nine sites (64.3%) showed
the same direction of effect across all cohorts.chiatry October 15, 2019; 86:599–607 www.sobp.org/journal 601
Table 1. Cohort Characteristics
Characteristic
Cohort
NTR
(N = 2258a)
Dunedin Study
(N = 800)
E-Risk Study
(N = 1631)
CAARS ADHD Index 7.9 (3.9) – –
DSM-5 Adult ADHD
Symptoms
– 1.5 (2.3) 5.8 (4.3)
Age at Blood
Sampling,
Years
37.3 (12.9) 38 (0) 18 (0)
Sex, Female 1549 (69.0%) 392 (49.0%) 817 (50.1%)
Current Smokerb 438 (19.4%) 162 (20.3%) 372 (22.8%)
Former Smoker 532 (23.6%) 233 (29.1%) –
Never Smoked 1288 (57.0%) 405 (50.6%) –
Nonsmokerb – – 1259 (77.2%)
Values are presented as mean (SD) or n (%).
ADHD, attention-deﬁcit/hyperactivity disorder; CAARS, Conners
Adult ADHD Rating Scale; NTR, Netherlands Twin Register.
aIn NTR, 2258 samples from 2232 individuals were included (for 26
individuals, two longitudinal DNA samples were included).
bIn E-Risk, the smoking variable that was included as covariate in
the analyses and that is presented in this table is current daily
smoking at age 18.
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In sensitivity analyses, the association with inattention and
hyperactivity/impulsivity subscales, separately, was tested in
NTR for the three top DMPs from the meta-analysis. This
analysis showed that the direction of effect and the strength of
the association with each of the subscales was highly similar
(Table S5 in Supplement 2).
Enrichment of EWAS and GWAS Loci
In testing for overlap of our EWAS meta-analysis results with
ﬁndings from previous EWASs and GWASs, we failed to
observe enrichment of CpGs previously associated with lon-
gitudinal ADHD trajectories in children (16) or schizophrenia in
adults (53); CpGs associated with individual (31) or maternal
smoking (30); and CpGs near GWAS loci for ADHD, autism
spectrum disorder, major depressive disorder, or schizo-
phrenia (Table S6 in Supplement 2). Methylation sites previ-
ously associated with schizophrenia (53) showed a small but
signiﬁcant depletion of signal for ADHD symptoms.
Differentially Methylated Regions
In NTR, six signiﬁcant DMRs were identiﬁed, which spanned
from 164 to 848 bp and included 3 to 32 CpGs (Table 3;Table 2. Top DMPs From EWAS Meta-analysis
cgID CHR Positiona Gene Location N
cg26197679 8 142310085 – Intergenic LI
cg23144852 3 193405999 OPA1 Gene body OP
cg10984962 2 236462202 AGAP1 Gene body AG
CpGs with a p value , 1.0 3 1025 are shown.
CHR, chromosome; DMPs, differentially methylated positions; EWAS,
2, negative direction of effect.
aGenome build Hg19 (build 37).
bTotal sample size in the meta-analysis.
602 Biological Psychiatry October 15, 2019; 86:599–607 www.sobp.orTable S7 in Supplement 2). One example is illustrated in
Figure S3 in Supplement 1. In the Dunedin study, 19 signiﬁcant
DMRs were identiﬁed, spanning from 2 to 51 CpGs within re-
gions of 18 to 1818 bp (Table 3; Table S7 in Supplement 2). In
E-Risk, no signiﬁcant DMRs were identiﬁed. Six distinct DMRs
were detected in the major histocompatibility complex (MHC)
region (chromosome 6): three in NTR and three in the Dunedin
study. In line with the heterogeneity of DMP results across
cohorts, none of the DMRs detected in NTR and Dunedin
overlapped, and DMR analysis on the meta-analysis of the
three cohorts did not detect signiﬁcant DMRs.
Signiﬁcant DMRs did not overlap with CpGs from the pre-
vious EWAS of ADHD trajectories in children (16) or with
schizophrenia in adults (53). One of the six DMRs identiﬁed in
NTR (chromosome 6: 33245460 to 3324630) contained CpGs
previously associated with smoking (12 of the 32 CpGs) and
maternal smoking (3 CpGs). Five of the 19 DMRs identiﬁed in
the Dunedin study contained CpGs associated with smoking
or maternal smoking (Table S7 in Supplement 2).
Several DMRs were located in proximity of SNPs associated
with schizophrenia (51). Of the DMRs in NTR, two were located
within 100 kb and one was located within 1 Mb of
schizophrenia-associated SNPs, respectively (all in the MHC
region). Five DMRs in the Dunedin study were located within 1
Mb of schizophrenia-associated SNPs (two on chromosome 6,
two on chromosome 7, and one on chromosome 15). None of
the DMRs was located within 1 Mb of signiﬁcant GWAS loci for
ADHD, major depressive disorder, or autism spectrum disorder.
Gene Expression in cis
To examine potential functional consequences of top DMPs
and DMRs, we used previously published data on whole-blood
DNA methylation and RNA sequencing (n = 2101 samples).
Whereas DNA methylation levels at the ADHD symptom level
top DMPs were not associated with RNA levels of genes in cis,
methylation levels at CpGs within ﬁve of the six signiﬁcant
DMRs detected in NTR were associated with expression levels
of 14 genes (Table 3; Table S8 in Supplement 2). At one DMR,
higher methylation level correlated with lower expression; at
another DMR, higher methylation level correlated with higher
expression; and at three DMRs, expression of some genes
correlated positively and others negatively with methylation
level. Of the 19 DMRs identiﬁed in the Dunedin study, the
methylation levels at CpGs within three DMRs were associated
with expression levels of seven genes (Table 3; Table S9 in
Supplement 2). At two DMRs, a higher methylation level
correlated with lower expression, and at one DMR, a higher
methylation level correlated with higher expression.earest Gene Weightb Z Score p Value Direction
NC01300 4689 24.9 1.1 3 1026 222
A1 4684 24.8 1.7 3 1026 222
AP1 4688 4.5 9.7 3 1026 111
epigenome-wide association study; 1, positive direction of effect;
g/journal
Table 3. Signiﬁcant DMRs Associated With ADHD Symptoms
CHR Start End
Probes
(n)a
Region
Size (bp)
Region Sidák
p Value Genesb
Gene Expression
Associated With CpGs
Netherlands Twin Register
6 31650735 31651363 19 628 4.3 3 10210 – LY6G5C, DDAH2, AIF1, C6orf48, LST1,
VWA7, HSPA1L, PRRC2A, MICB
11 67417958 67418406 11 448 7.6 3 1029 ACY3 ACY3
6 31583915 31584224 4 309 1.2 3 1026 AIF1 AIF1, LY6G5C, C6orf48, PRRC2A, LST1,
LY6G5C, VWA7, BAG6, HSPA1L
6 33245460 33246308 32 848 3.0 3 1025 B3GALT4 B3GALT4, RPS18
13 113613574 113613738 3 164 4.8 3 1025 – –
3 48632484 48633145 11 661 2.1 3 1024 COL7A1 COL7A1
Dunedin Study
6 32063394 32065212 51 1818 2.3 3 10217 TNXB SKIV2L, C4B, C4A, TNXB, TNXA
5 191127 192104 12 977 4.4 3 10211 LRRC14B –
19 17931932 17932370 8 438 2.3 3 1028 INSL3 –
20 748992 749621 8 629 4.9 3 1028 C20orf54 –
6 32847441 32847846 16 405 1.3 3 1026 PPP1R2P1 HLA-DQA
15 75019070 75019377 10 307 4.8 3 1026 CYP1A1 –
4 56458183 56458623 7 440 5.1 3 1026 PDCL2 –
11 1769152 1769646 9 494 6.8 3 1026 HCCA2; LOC402778;
LOC402778
–
4 186732837 186733332 8 495 8.9 3 1026 SORBS2 –
15 90727560 90728141 9 581 5.5 3 1025 SEMA4B SEMA4B
7 1250038 1250757 10 719 6.4 3 1025 – –
7 2728344 2728913 4 569 8.8 3 1025 AMZ1 –
8 41655673 41656080 6 407 1.5 3 1024 ANK1 –
12 25801455 25801622 4 167 3.5 3 1024 IFLTD1 –
6 3247958 3248099 2 141 2.3 3 1023 – –
14 96670628 96671170 11 542 3.9 3 1023 BDKRB2 –
20 22795685 22795775 2 90 8.7 3 1023 – –
4 187985377 187985473 2 96 .02 – –
8 1993528 1993546 2 18 .03 MYOM2 –
More detailed information on the regions is provided in Table S7 in Supplement 2. More detailed results for the association between DNA
methylation levels and gene expression in cis is provided in Table S8 in Supplement 2 (Netherlands Twin Register) and Table S9 in Supplement
2 (Dunedin study). No signiﬁcant DMRs were found in E-Risk.
ADHD, attention-deﬁcit/hyperactivity disorder; CHR, chromosome; DMRs, differentially methylation regions.
aTotal number of methylation sites in the window.
bGenes mapping to CpGs in the window.
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To gain insight into genetic causes of variation underlying top
DMPs and DMRs, we obtained whole-blood mQTL data (n =
3841 samples) (55). One of the three top DMPs from the ADHD
symptom meta-analysis was associated with six independent
SNPs (mQTLs) in cis (Table S10 in Supplement 2). The majority
of DMRs (92.0%; 23) was associated with mQTLs. For ADHD-
associated DMRs in NTR, on average 68% of the CpGs within
a DMR (range, 36.4%–92.3%) was associated with at least one
mQTL SNP. A total of 164mQTL associationswere identiﬁed for
NTR DMRs (76.8% were cis mQTLs and 23.2% were trans
mQTLs) (Table S11 in Supplement 2), involving 59 CpGs and 55
SNPs. For ADHD-associated DMRs in Dunedin, 323 mQTL
associations were identiﬁed, involving 126 CpGs and 154 SNPs
(88% cis and 13% trans) (Table S12 in Supplement 2). On
average, 64.9% (range, 0%–100%) of CpGs within DMRs
identiﬁed in the Dunedin study was associated with one or more
mQTLs. We highlight one example: a DMR on chromosome 11,Biological Psydetected in NTR and associated with the expression of ACY3,
was associated with cis and trans mQTLs, and the correlation
structure of DNA methylation within this DMR (Figure S2 in
Supplement 2) mirrored the sharing across CpGs of trans-
mQTLs on chromosome 6 (Figure S3 in Supplement 2).
Comparing the overlap of mQTLs across cohorts revealed that
two DMRs were associated with a common set of transmQTLs.
The DMR on chromosome 11 in NTR (associated with expres-
sion of ACY3) and the DMR on chromosome 15 in Dunedin
(associated with expression of SEMA4B) were both associated
in transwith SNPs on chromosome 6: 109626965 to 109616420
(rs9374080, rs1008084, and rs9386791).
Correlation Between DNA Methylation Level in
Blood and Brain
Whereas DNA methylation levels at the ADHD symptom top
DMPs did not correlate signiﬁcantly between blood and
brain, CpGs within 4 of the 6 DMRs (66.7%) detected inchiatry October 15, 2019; 86:599–607 www.sobp.org/journal 603
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(68.4%) detected in the Dunedin study (Table S14 in
Supplement 2) showed signiﬁcantly correlated DNA
methylation levels between blood and one or multiple brain
regions. For all CpGs except for one, the correlation was
positive (mean r = .50; range, 2.42 to .70). The number of
CpGs per DMR that showed correlated methylation levels
between blood and brain ranged from 1 to 31 (mean 5.5).
The DMR with the largest number of CpGs with signiﬁcant
blood-brain correlations (31 CpGs) was a DMR in the MHC
region detected in the Dunedin study and associated with
the expression level of multiple genes, including C4A and
C4B. An exemplary plot of methylation levels in blood and
brain for one CpG in this region (cg01337207) is provided in
Figure S5 in Supplement 1.DISCUSSION
We performed an EWAS of ADHD symptoms in three
population-based adult cohorts. Our hypothesis was that DNA
methylation in blood may provide insight into epigenetic con-
sequences of life conditions that correlate with ADHD symp-
toms and potentially into epigenetic mechanisms that
contribute to ADHD symptoms or that correlate with causal
epigenetic mechanisms in the brain. In the Dunedin study, we
identiﬁed one signiﬁcant DMP where a higher methylation level
correlated with fewer ADHD symptoms (cg26197679, chromo-
some 8 intergenic). This CpG as well as other top-ranking CpGs
from individual cohorts showed considerable heterogeneity,
and no signiﬁcant DMPswere detected in a meta-analysis of the
three cohorts. In secondary region-based analyses, we tested if
ADHD symptoms were associated with methylation differences
at multiple nearby CpGs that individually failed to reach
epigenome-wide signiﬁcance. We identiﬁed six signiﬁcant
DMRs in NTR, 19 in the Dunedin study, and none in E-Risk. In
line with the heterogeneity of DMP results, none of the DMRs
overlapped across cohorts, and the meta-analysis–based DMR
analysis did not detect signiﬁcant DMRs. With respect to effects
of differential exposures, although the EWAS signal showed no
signiﬁcant enrichment for CpGs previously associated with
smoking, some DMRs contained CpGs previously associated
with smoking (31) or maternal smoking (30), even after we
adjusted for smoking. There are several possible explanations
for this ﬁnding (56): 1) residual confounding effects of smoking;
2) second-hand smoking exposure, including maternal prenatal
smoking; 3) exposures other than smoking; for instance, ADHD
is associated with general substance use (57); and 4) these
CpGs are connected to a shared underlying biology of ADHD
symptoms and smoking. Importantly, the current study shows
that effects of mQTLs and correlated methylation levels be-
tween blood and brain exceed effects of smoking: 92% of
DMRs were associated with genetic variants, 68% of DMRs
showed correlated methylation levels between blood and brain
regions, and 24% of DMRs were associated with smoking.
These observations suggest that interindividual differences in
DNA methylation at these DMRs are not merely driven by life-
style differences associated with ADHD symptoms, such as
smoking, and that some of the methylation differences in whole
blood associated with ADHD symptoms may be a marker for
methylation variation in the brain.604 Biological Psychiatry October 15, 2019; 86:599–607 www.sobp.orSome top DMPs and top DMRs mapped to genes that have
been previously linked to psychiatric disorders or implicated in
brain biology. These are potential candidates for being
involved in the underlying biology of ADHD symptoms, pro-
vided that these loci also show symptom-associated differ-
ences in epigenetic regulation in the brain. For instance,
cg10984962, the third-ranking CpG from the meta-analysis, is
located in AGAP1, which encodes a protein involved in
endosomal trafﬁcking. In neuronal cells, it plays a role in the
recycling of muscarinic acetylcholine receptors (58) and was
shown to inﬂuence dendritic spine morphology (59). Yet,
methylation levels in blood did not correlate with methylation
levels in the brain at this CpG. Six signiﬁcant DMRs in distinct
subregions of the MHC were identiﬁed in NTR and the Dun-
edin Study. The top DMR in MHC in the Dunedin study was
associated with expression levels of SKIV2L, C4B, C4A,
TNXB, and TNXA. CpGs in this DMR were not associated with
smoking (31). The C4 genes are of great interest, as they have
been previously implicated in functional effects of
schizophrenia-associated SNPs in the MHC on postnatal
synaptic pruning (60). At many CpGs in this DMR, DNA
methylation levels in blood showed moderate to strong cor-
relations with DNA methylation levels in multiple brain regions.
However, as the DMRs did not replicate across cohorts, it
remains to be established whether they are relevant to ADHD
symptom levels.
The lack of overlap of our ﬁndings with CpGs from a pre-
vious study, in which methylation level in cord blood signiﬁ-
cantly predicted ADHD trajectories in childhood (16), could
indicate that epigenetic associations relevant to ADHD symp-
toms are age speciﬁc [which has already been described for
genetic contributions to ADHD symptoms (61)]. The loci
detected in cord blood also did not show an association with
ADHD symptoms when methylation was assessed at age 7
years in the previous study (16). Age-speciﬁc epigenetic as-
sociations may also potentially explain a lack of overlap with
GWAS loci. Whereas our EWAS included only adults, the
GWAS of ADHD contained mainly children (4).
This is the ﬁrst EWAS of ADHD symptoms in adults, the
largest epigenetic study of ADHD symptoms to date, and the
ﬁrst study of ADHD symptoms to apply a multicohort
approach. This study also has limitations. Although all co-
horts included adults and applied continuous measures of
ADHD symptoms reported by the same informant (self-
report), there were also differences between cohorts that may
have reduced power. First, CAARS was used in NTR, which
is based on DSM-IV, whereas DSM-5 symptoms were
assessed in the E-Risk and Dunedin study. Second, ADHD
symptoms were assessed by a self-report scale in NTR and
by structured interviews in the Dunedin study and E-Risk.
Third, DNA methylation measurements, processing of data,
and quality control were performed separately in each cohort,
based on quality control and normalization pipelines that
were optimized for each cohort. Fourth, cohorts varied in age
and reported number of ADHD symptoms. NTR included a
broad age range (mean age 37 years), whereas participants
from the E-Risk study were young adults (age 18 years), and
the age of participants from the Dunedin study was 38 years.
The prevalence of ADHD in these cohorts, based on the in-
struments used in the current study, has been previouslyg/journal
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8% in E-Risk (43). Fifth, the cohorts were from different
countries, and it is possible that epigenetic differences exist
between cohorts owing to differences in genetic background
or in the presence and frequency of environmental
exposures.
We performed a power analysis for the three meta-analysis
top DMPs, based on their effect size observed in NTR
(Figure S6 in Supplement 1). The effect sizes of these three
DMPs ranged from 0.09% to 0.92% explained variance. For
the top DMP that showed the least heterogeneity
(cg10984962; AGAP1; variance explained 0.28% in NTR), the
required sample size to achieve 80% power is 13,508. Similar
to our population-based EWAS of ADHD symptoms, a recent
blood-based EWAS meta-analysis of cognitive abilities iden-
tiﬁed only a few signiﬁcant sites for most cognitive measures in
.6000 individuals (63).
Several limitations apply to epigenetic epidemiology
studies, including ours. First, the HumanMethylation450K
array captures only approximately 1.7% of all CpGs in the
genome, and the removal of methylation probes that overlap
with genetic polymorphisms, albeit inevitable because these
polymorphisms compromise the quality of microarray-based
measurements of DNA methylation, may limit the ability to
detect DNA methylation–mediated SNP effects on the
phenotype. Second, blood is unlikely to provide a complete
picture of ADHD-related epigenetic processes because
epigenetic markers are largely tissue speciﬁc. Yet, methyl-
ation changes in blood have already been associated with
ADHD symptoms (16), other psychiatric conditions (53),
cognition (63), and hippocampal volume (64) in earlier
studies. Furthermore, we found that several of the DMRs
detected in blood contain CpGs with correlated methylation
levels across blood and brain. Finally, a general constraint in
epigenetic studies is that trait-associated variation in DNA
methylation may arise secondary to trait development
(reverse causality) or may be a marker of trait-associated
environmental exposures (lifestyle; medication use; in-
fections; and early life environmental factors, such as nutri-
tion and maternal smoking). These associations nevertheless
may provide valuable insight into the underlying biological
changes associated with ADHD and its risk factors. The
(direction of) causality may be addressed in human studies,
for example, with longitudinal study designs or Mendelian
randomization (65).
In conclusion, by performing an EWASof ADHD symptoms in
three population-based adult cohorts, we found no signiﬁcant
sites in an EWAS meta-analysis of 4689 individuals and
observed considerable heterogeneity of effects across cohorts.
We found several signiﬁcant cohort-speciﬁc DMPs and DMRs,
with the MHC region emerging in two cohorts. The signiﬁcance
of these ﬁndings is unknown, but they may point at new
candidate pathways awaiting further replication. Larger studies
are necessary to identify methylation sites in whole blood that
are robustly associated with population-based ADHD symp-
toms in adults. Our ﬁndings also illustrate the need for further
research to examine towhat extent epigenetic associationswith
psychiatric traits depend on characteristics such as age, sex,
lifetime exposures, genetic background, symptom severity, and
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